

15. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. *Protein Eng Des Sel*. 2011;24:3–9.
16. Donnelly DJ, Smith RA, Morin P, et al. Synthesis and biologic evaluation of a novel ¹⁸F-labeled adnectin as a PET radioligand for imaging PD-L1 expression. *J Nucl Med*. 2018;59:529–535.
17. Lee S-J, Jang B-C, Lee S-W, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). *FEBS Lett*. 2006;580:755–762.
18. Caumanns JJ, van Wijngaarden A, Kol A, et al. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. *Cancer Lett*. 2019;461:102–111.
19. Stutvoet TS, Kol A, de Vries EG, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. *J Pathol*. 2019;249:52–64.
20. González Trotter DE, Meng X, McQuade P, et al. In vivo imaging of the programmed death ligand 1 by ¹⁸F PET. *J Nucl Med*. 2017;58:1852–1857.
21. Natarajan A, Patel CB, Ramakrishnan S, Panesar PS, Long SR, Gambhir SS. A novel engineered small protein for positron emission tomography imaging of human programmed death ligand-1: validation in mouse models and human cancer tissues. *Clin Cancer Res*. 2019;25:1774–1785.
22. Kumar D, Lisok A, Dahmane E, et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. *J Clin Invest*. 2019;129:616–630.
23. Lv G, Sun X, Qiu L, et al. PET imaging of tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. *J Nucl Med*. 2020;61:117–122.
24. Maute RL, Gordon SR, Mayer AT, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. *Proc Natl Acad Sci USA*. 2015;112:E6506–E6514.
25. Broos K, Keyaerts M, Lecocq Q, et al. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. *Oncotarget*. 2017;8:41932–41946.
26. Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. *Cell Rep*. 2017;19:1189–1201.
27. Maleki Vareki S, Chen D, Di Cresce C, et al. IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells. *PLoS One*. 2015;10:e0143435.
28. Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. *Theranostics*. 2016;6:1629–1640.
29. Li C-W, Lim S-O, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. *Nat Commun*. 2016;7:12632.
30. Horita H, Law A, Hong S, Middleton K. Identifying regulatory posttranslational modifications of PD-L1: a focus on monoubiquitination. *Neoplasia*. 2017;19:346–353.
31. Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. *Nature*. 2017;549:106–110.
32. Varthaman A, Moreau HD, Maurin M, Benaroch P. TLR3-induced maturation of murine dendritic cells regulates CTL responses by modulating PD-L1 trafficking. *PLoS One*. 2016;11:e0167057.
33. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy: blockade, knockdown, or inhibition. *Front Immunol*. 2019;10:2022.
34. Bensch F, van der Veen EL, Lub-de Hooge MN, et al. ⁸⁹Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med*. 2018;24:1852–1858.
35. Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. *Nat Commun*. 2018;9:4664.
36. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. *FASEB J*. 2008;22:276–284.

Erratum

In the article “Ventricular Tachycardia (VT) Substrate Characteristics: Insights from Multimodality Structural and Functional Imaging of the VT Substrate Using Cardiac MRI Scar, ¹²³I-Metaiodobenzylguanidine SPECT Innervation, and Bipolar Voltage, by Imanli et al. (*J Nucl Med*. 2019;60:79–85), an affiliation for author Yousra Ghzally was inadvertently left off of the affiliation list. The affiliations for Dr. Yousra Ghzally should have included: Assiut University, Arab Republic of Egypt. The authors regret the error.